Carolina S Ilkow

List of Publications by Citations

Source: https://exaly.com/author-pdf/8850817/carolina-s-ilkow-publications-by-citations.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35 papers	1,106 citations	16 h-index	33 g-index
42 ext. papers	1,336 ext. citations	10.8 avg, IF	3.79 L-index

#	Paper	IF	Citations
35	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. *Molecular Therapy*, **2012**, 20, 749-58	11.7	177
34	Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. *Cancer Research*, **2013**, 73, 1265-75	10.1	160
33	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. *Nature Medicine*, **2015**, 21, 530-6	50.5	93
32	Smac mimetics and innate immune stimuli synergize to promote tumor death. *Nature Biotechnology* , **2014**, 32, 182-90	44.5	92
31	Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy. *EBioMedicine*, **2018**, 31, 17-24	8.8	68
30	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. *Cancer Cell*, **2015**, 28, 210-24	24.3	62
29	Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. *Molecular Therapy*, **2015**, 23, 1066-1076	11.7	54
28	From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. *PLoS Pathogens*, **2014**, 10, e1003836	7.6	48
27	Rubella virus capsid protein interacts with poly(a)-binding protein and inhibits translation. *Journal of Virology*, **2008**, 82, 4284-94	6.6	46
26	Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. *Molecular Therapy*, **2014**, 22, 1320-1332	11.7	43
25	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. *Nature Communications*, **2015**, 6, 6410	17.4	36
24	The Rubella virus capsid is an anti-apoptotic protein that attenuates the pore-forming ability of Bax. *PLoS Pathogens*, **2011**, 7, e1001291	7.6	30
23	Dimethyl fumarate potentiates oncolytic virotherapy through NF-B inhibition. *Science Translational Medicine*, **2018**, 10,	17.5	28
22	The rubella virus capsid protein inhibits mitochondrial import. *Journal of Virology*, **2010**, 84, 119-30	6.6	28
21	Modulation of signaling pathways by RNA virus capsid proteins. *Cellular Signalling*, **2008**, 20, 1227-36	4.9	17
20	Analyses of phosphorylation events in the rubella virus capsid protein: role in early replication events. *Journal of Virology*, **2006**, 80, 6917-25	6.6	17
19	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2S for viral entry. *Molecular Therapy*, **2021**, 29, 1984-2000	11.7	13

18	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. *Molecular Therapy - Oncolytics*, **2019**, 14, 179-187	6.4	11
17	Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	11
16	Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization. *Membranes*, **2020**, 10,	3.8	10
15	Rubella virus capsid protein: a small protein with big functions. *Future Microbiology*, **2010**, 5, 571-84	2.9	9
14	SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. *Biosensors and Bioelectronics*, **2021**, 180, 113122	11.8	9
13	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. *Molecular Therapy - Oncolytics*, **2016**, 3, 16027	6.4	9
12	A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma. *Cancer Cell*, **2017**, 32, 133-134	24.3	7
11	Phosphorylation and membrane association of the Rubella virus capsid protein is important for its anti-apoptotic function. *Cellular Microbiology*, **2014**, 16, 1201-10	3.9	6
10	Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis. *Cancers*, **2020**, 12,	6.6	6
9	Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference **2018**, 6, 62		5
8	A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion. *Nanomaterials*, **2021**, 11,	5.4	5
7	Single-dose replicating poxvirus vector-basedRBD vaccine drives robust humoral and T□cellimmune response against SARS-CoV-2 infection. *Molecular Therapy*, **2021**,	11.7	2
6	Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. *Cytokine and Growth Factor Reviews*, **2020**, 56, 102-114	17.9	2
5	Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic. *ACS Nanoscience Au*,		1
4	Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer.. *Molecular Therapy - Oncolytics*, **2022**, 24, 507-521	6.4	0
3	Personalized oncology and BRAF melanoma: model development, drug discovery, and clinical correlation. *Journal of Cancer Research and Clinical Oncology*, **2021**, 147, 1365-1378	4.9	0
2	Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.. *Nature Communications*, **2022**, 13, 1898	17.4	0
1	Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses. *Methods in Molecular Biology*, **2020**, 2058, 271-284	1.4	